254.06
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $254.06, with a volume of 1.26M.
It is up +0.14% in the last 24 hours and up +9.25% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$253.71
Open:
$254.81
24h Volume:
1.26M
Relative Volume:
0.88
Market Cap:
$58.83B
Revenue:
$250.74B
Net Income/Loss:
$1.55B
P/E Ratio:
38.85
EPS:
6.5398
Net Cash Flow:
$4.39B
1W Performance:
+6.94%
1M Performance:
+9.25%
6M Performance:
+19.22%
1Y Performance:
+65.76%
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH vs MCK, COR, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CAH
Cardinal Health Inc
|
254.06 | 58.83B | 250.74B | 1.55B | 4.39B | 6.5398 |
|
MCK
Mckesson Corp
|
1,004.84 | 117.15B | 403.43B | 5.10B | 5.41B | 38.47 |
|
COR
Cencora Inc
|
340.92 | 65.06B | 328.68B | 2.55B | 1.56B | 13.03 |
|
HSIC
Henry Schein Inc
|
86.38 | 9.63B | 13.38B | 418.00M | 391.00M | 3.3112 |
|
AHG
Akso Health Group Adr
|
1.35 | 1.16B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-26 | Initiated | RBC Capital Mkts | Outperform |
| Apr-28-26 | Initiated | William Blair | Outperform |
| Jan-09-26 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Cardinal Health stock: Baird's USD 276.00 target leaves Cardinal Health stock 8.09 percent below it - ad-hoc-news.de
Cardinal Health extends CVS deal. Cardinal Health stock costs EUR 226.20 not valid? wait - ad-hoc-news.de
Could Cardinal Health (NYSE:CAH) Be in Focus After Wall Street’s Latest Rotation? - Kalkine Media
Cardinal Health (CAH) Laps the Stock Market: Here's Why - Zacks Investment Research
Cardinal Health (CAH) Laps the Stock Market: Here's Why - Yahoo Finance
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge - Zacks Investment Research
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Cardinal Health Inc (CAH) Shares Surge 3.4% -- What GF Score of 78 Tells Investors - GuruFocus
Cardinal Health Inc. stock outperforms competitors on strong trading day - MarketWatch
Deals tracker: Harbor Health to buy 27 Village Medical clinics - Modern Healthcare
What to Expect From Cardinal Health’s Q1 2027 Earnings Report - Yahoo Finance
What to Expect From Cardinal Health’s Q1 2027 Earnings Report - inkl
Cardinal Health, Inc. (CAH) options chain – Yahoo Finance - Yahoo Finance Singapore
Cardinal Health Could Benefit From RayzeBio's Phase 3 Success, RBC Says - www.marketscreener.com
Here's Why Cardinal Health (CAH) is a Strong Growth Stock - Zacks Investment Research
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
Should Value Investors Buy Cardinal Health (CAH) Stock? - Yahoo Finance
China Patient Examination Devices Market Size, Share, and Forecast to 2033Thermometers and Stethoscopes | Pricing Trends and Growth Opportunities Guide Expansion - GlobeNewswire Inc.
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now - Zacks Investment Research
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Freehand CEO Nitin Jayakrishnan Addresses Supply Chain Disruption and Resilience at LogiPharma USA 2026 - GlobeNewswire Inc.
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now - Yahoo Finance
Cardinal Health (CAH) Outperforms Broader Market: What You Need to Know - Zacks Investment Research
Cardinal Health stock gains 1.59 percent after CVS pact - AD HOC NEWS
Cardinal Health, Inc. (CAH) Stock Forecasts - Yahoo! Finance Canada
Cardinal Health agrees to extend CVS deal: Cardinal Health stock gains 1.33 percent - AD HOC NEWS
Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex - Zacks Investment Research
CVS renews as Cardinal Health’s largest customer through 2032 - bizjournals.com
Is Cardinal Health Inc (CAH) Overvalued After 3.4% Rally? GF Val - gurufocus.com
Cardinal Health Inc. stock outperforms competitors on strong trading day - MarketWatch
Cardinal Health, Inc. (CAH) Stock Forecasts - Yahoo Finance
Cardinal Health, Inc. (CAH) Stock Forecasts - Yahoo! Finance Canada
Cardinal Health rises on extended CVS distribution deal - Investing.com
Cardinal Health, McKesson Extend Distribution Pacts With CVS Through 2032 - finance.biggo.com
McKesson and Cardinal Health: CVS Contract Renewal Reaffirms Narrow Moat and Long-Term Growth - Morningstar
Why Is Cardinal Health and McKesson Stock Trading Higher TodayCVS Health (NYSE:CVS), McKesson (NYSE:MC - Benzinga
Why Is Cardinal Health and McKesson Stock Trading Higher TodayCVS Health (NYSE:CVS), McKesson (NYSE:MC - Benzinga
Cardinal Health renews contract with CVS Health - marketscreener.com
Cardinal Health Extends CVS Health Pharmaceutical Distribution Agreement Through 2032 - Yahoo Finance
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve - Zacks Investment Research
Cardinal Health (CAH) Extends CVS Distribution Deal Through 2032, Reaffirms FY2027 EPS Guidance - gurufocus.com
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health - Yahoo Finance
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5 - Yahoo! Finance Canada
Cardinal Health rises on extended CVS distribution deal - Yahoo Finance
Cardinal Health: I'm Still Buying After Checking The Numbers (NYSE:CAH) - Seeking Alpha
Total debt per share of Cardinal Health, Inc. – HAN:CLH - TradingView
Cardinal Health Inc. stock outperforms competitors on strong trading day - MarketWatch
Cardinal Health (CAH): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Cardinal Health (CAH): Buy, Sell, or Hold Post Q2 Earnings? - The Globe and Mail
At-Home Healthcare Is Growing Fast: Can CAH Ride the Trend? - TradingView
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardinal Health Inc Stock (CAH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hollar Jason M. | Chief Executive Officer |
Aug 19 '26 |
Sale |
236.18 |
44,529 |
10,516,660 |
190,603 |
| Mary Scherer | Officer |
Aug 19 '26 |
Proposed Sale |
237.39 |
2,302 |
546,462 |
0 |
| WEITZMAN DEBORAH | CEO, PSS Segment |
Aug 18 '26 |
Sale |
235.45 |
7,354 |
1,731,524 |
77,901 |
| Alt Aaron E | Chief Financial Officer |
Aug 18 '26 |
Sale |
236.34 |
42,000 |
9,926,140 |
20,495 |
| Mayer Jessica L | Chief Legal/Compliance Officer |
Aug 18 '26 |
Sale |
236.19 |
29,436 |
6,952,485 |
33,076 |
| Greene Michelle D. | Chief Information Officer |
Aug 18 '26 |
Sale |
235.72 |
11,650 |
2,746,187 |
10,330 |
| Aaron Alt | Officer |
Aug 18 '26 |
Proposed Sale |
236.34 |
42,000 |
9,926,183 |
0 |
| Michelle Greene | Officer |
Aug 18 '26 |
Proposed Sale |
235.72 |
11,650 |
2,746,148 |
0 |
| Deborah Weitzman | Officer |
Aug 18 '26 |
Proposed Sale |
235.45 |
7,354 |
1,731,534 |
0 |
| Jessica Mayer | Officer |
Aug 18 '26 |
Proposed Sale |
236.19 |
29,436 |
6,952,441 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):